Search This Blog

Wednesday, February 19, 2014

Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival (NYSE:LLY)

Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.